Abeona Therapeutics Nears Transformative FDA Decision

Statement to Readers on Abeona (ABEO) Prediction

We know many of you were watching Abeona Therapeutics (ABEO) closely, expecting a major breakout based on our July prediction. At that time, Orbo projected a sharp move tied to the FDA decision on their gene therapy pz-cel, with a price target of $10.
Here’s what actually happened:

• The FDA did approve pz-cel (ZEVASKYN) on April 29, 2025 — the transformative catalyst we were waiting for.
• However, the stock did not deliver the predicted breakout during the July–August investment window. Instead, ABEO drifted slightly lower and has remained in the mid-$5 range.

Why the miss? Orbo was correct in identifying the catalyst, but it misjudged the timing and market impact. The approval was already well-anticipated by the market, so much of the upside was priced in before our prediction window. After approval, the focus shifted to commercialization and reimbursement challenges — factors that dampened immediate price movement.
This is an important reminder:

• Catalysts do not always equal instant breakouts.
• Market reactions depend not just on approval, but also on execution, adoption, and financing.
• Even strong predictions can be affected by timing, broader market sentiment, and pre-priced expectations.

We remain committed to learning from these cases. Each “miss” improves the system. In this case, the insight is that regulatory approvals may sometimes be fully priced in well before the window we set, and we need to adjust Orbo’s timing models accordingly.
Thank you for staying with us on this journey. Together, we’re refining a tool that is getting sharper every cycle — even when the market reminds us it has its own rhythm.